Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in the August 2011 issue of Nature Biotechnology titled “US Court Bolsters Biotech Patent Protection.” Brinckerhoff discusses the outcome of Therasense vs. Becton Dickinson & Company and its significance to biotech companies. She observes that the decision offers patent holders a new basis for defeating an inequitable conduct charge, but adds that litigants are likely to continue raising the defense in order to render an entire patent unenforceable until more court decisions have rejected weaker charges of inequitable conduct.
People
Related News
December 12, 2025
In the News
Foley Chairman and CEO Daljit Doogal Talks Firm Strategy and Growth, Featured in Media for Reelection
Foley & Lardner LLP Chairman and CEO Daljit Doogal is featured in The American Lawyer article, “Foley Board Taps Daljit Doogal for Second Term as Chair and CEO,” for his reelection to a second four-year term.
December 11, 2025
In the News
Carrie Hoffman Comments on SCOTUS Arbitration Jurisdiction Case
Foley & Lardner LLP partner Carrie Hoffman commented on the U.S. Supreme Court's decision to hear an arbitration jurisdiction case in the Law360 article, "High Court Arb. Jurisdiction Case May Impact W&H Cases."
December 10, 2025
In the News
Charles Gass Quoted on Health Care Implications of Colorado AI Act
Foley & Lardner LLP senior counsel Charles Gass detailed Colorado's Artificial Intelligence Act and its implications for health providers in the ColoradoBiz article, “Colorado leads nation on AI healthcare regulations.”